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Background:  Bioprostetic valve replacement is the treatment of choice in elderly patients with symptomatic aortic valve stenosis. 
Recommendations regarding postoperative anticoagulant therapy include three months of vitamin K antagonist or acetylsalicylic acid (ASA). The 
incidence and treatment of chronic valve thrombosis in these patients have not been reported previously.
Methods:  At our hospital 789 patients received a bioprosthetic aortic valve between 2007 and 2009. The recommended postoperative 
anticoagulant therapy was three months of vitamin K antagonist (phenprocoumon) with an INR of 2-3 or ASA 100mg daily.
Results:  Eight patients (1%) presented predominantly with dyspnea 267±112 days postoperatively and were diagnosed echocardiographically with 
chronic thrombosis of their valve prosthesis. Mean pressure gradient had increased from 22±5mmHg to 55±9mmHg (p<0.001). Transesophageal 
echocardiography was non-diagnostic in one third of patients due to shadowing. Seven patients were started on phenprocoumon with complete 
resolution of symptoms. Mean pressure gradient, measured 102±49 days later, was 22±6mmHg. Neither valve type (Epic vs. Mosaic) nor initial 
choice of anticoagulant (phenprocoumon vs. ASA) was predictive of valve thrombosis. One patient, who presented with dyspnea and fever, underwent 
emergency repeat valve replacement for suspected endocarditis with histology showing chronic thrombosis of the explanted valve.
Conclusion: Chronic thrombosis of bioprosthetic aortic valves occurs in at least 1% of patients during the first postoperative year. Anticoagulation 
with a vitamin K antagonist is an effective treatment in these patients.
